Key result
Oral anticoagulation therapy for stroke prevention in atrial fibrillation requires an individualized approach to balance the risks of ischemic stroke and intracranial hemorrhage.
This review summarizes current knowledge on oral anticoagulation therapy for stroke prevention in atrial fibrillation, emphasizing the need to balance ischemic stroke risk against bleeding risk on an individual basis.
Answers are grounded in this paper and cite their sources.
Supports individualized stroke-bleeding risk balancing with OAC in AF; leaves open optimal score selection for routine practice.
Oral anticoagulation therapy has reduced the risk of ischaemic stroke and improved the outcomes for patients with atrial fibrillation considerably. The emergence of the non-vitamin K oral anticoagulants as alternatives to vitamin K antagonists has significantly changed the practice of stroke prevention in atrial fibrillation. As the main complication with antithrombotic therapy is bleeding, physicians should always balance the risk of ischaemic stroke against intracranial haemorrhage and intervene where appropriate to reduce both risks. Individual approach is often mandatory due to heterogeneity of the risks and patient preferences. The purpose of this review is to summarise the current knowledge of the oral anticoagulation therapy in atrial fibrillation patients and guide physicians with the management of anticoagulants based on data from clinical trials and systematic reviews.
No takes yet. Share an insight, caveat, or question.
Voukalis et al. (2017) conducted a review in Atrial fibrillation. Oral anticoagulation therapy vs. Vitamin K antagonists was evaluated. Oral anticoagulation therapy for stroke prevention in atrial fibrillation requires an individualized approach to balance the risks of ischemic stroke and intracranial hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: